Bioinformatics-Driven mRNA-Based Vaccine Design for Controlling Tinea Cruris Induced by

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Immune-Based Prevention and Therapy Against Coccidioidomycosis: Current and Emerging Approaches.Journal of fungi (Basel, Switzerland) · 2026
   Review
2. Synthesis of an Adjuvant-Free Single Polypeptide-Based Tuberculosis Subunit Vaccine that Elicits In Vivo Immunogenicity in Rats.Molecular biotechnology · 2026
   Article
3. Advances in fungal vaccine development: Progress in the face of emerging challenges.iScience · 2025
   Review
4. Correction: Elalouf et al. Bioinformatics-Driven mRNA-Based Vaccine Design for Controlling Tinea Cruris Induced byPharmaceutics · 2024
   Article

Corrections and comments

• Erratum issued
  Correction: Elalouf et al. Bioinformatics-Driven mRNA-Based Vaccine Design for Controlling Tinea Cruris Induced by2024

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as